Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4601 Target Snapshot

Protein-tyrosine kinase 6 · SINGLE PROTEIN · Homo sapiens

1,877Compounds
324Assays
19Approved Drugs
1,185.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein-tyrosine kinase 6 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q13882. Start with cancer, then reuse UniProt Q13882 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt Q13882 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
cancer

Protein-tyrosine kinase 6 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with cancer because it currently carries approved-linked support. Linked drugs include VANDETANIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Protein-tyrosine kinase 6 as ChEMBL target CHEMBL4601, mapped to UniProt Q13882. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Protein-tyrosine kinase 6
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4601
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13882
Protein-tyrosine kinase 6
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Protein-tyrosine kinase 6 is the right protein anchor across sources, using UniProt Q13882 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelProtein-tyrosine kinase 6
UniProt AccessionQ13882
Component TypeProtein
Sequence Length451 aa

Protein-tyrosine kinase 6

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Protein-tyrosine kinase 6, mapped to UniProt Q13882. Sequence length is 451 aa.

Mapped IDQ13882
Review nameProtein-tyrosine kinase 6
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Protein-tyrosine kinase 6 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugVANDETANIB
Approved-linked Approved
medullary thyroid gland carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugVANDETANIB
Approved-linked Approved
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugVANDETANIB
Approved-linked Approved
papillary thyroid carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugVANDETANIB
Approved-linked Approved
thyroid cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugVANDETANIB
Approved-linked Approved
thyroid carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugVANDETANIB
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with cancer because it currently carries approved-linked support. Linked drugs include VANDETANIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

19
Approved
10
Phase III
14
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC50397.0
KI403.0
KD385.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1836842 8.7 IC50 2.0 Preclinical
CHEMBL5800577 8.7 IC50 2.0 Preclinical
CHEMBL5874804 8.7 IC50 2.0 Preclinical
CHEMBL450519 8.7 Kd 2.0 Preclinical
CHEMBL249097 8.7 Kd 2.0 Preclinical
CHEMBL5872498 8.68 IC50 2.1 Preclinical
CHEMBL5280844 8.6 IC50 2.5 Preclinical
CHEMBL1836806 8.52 IC50 3.0 Preclinical
CHEMBL1836854 8.52 IC50 3.0 Preclinical
CHEMBL1836863 8.52 IC50 3.0 Preclinical
Distribution

pChEMBL Value Distribution

26
5.0
51
5.5
58
6.0
52
6.5
83
7.0
42
7.5
67
8.0
16
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

ZANUBRUTINIB
CHEMBL3936761
Approved 2019
ENTRECTINIB
CHEMBL1983268
Approved 2019
BRIGATINIB
CHEMBL3545311
Approved 2017
TIVOZANIB
CHEMBL1289494
Approved 2017
LENVATINIB
CHEMBL1289601
Approved 2015
IBRUTINIB
CHEMBL1873475
Approved 2013
VANDETANIB
CHEMBL24828
Approved 2011
DASATINIB
CHEMBL5416410
Approved 2006
DASATINIB ANHYDROUS
CHEMBL1421
Approved 2006
GEFITINIB
CHEMBL939
Approved 2003
Assay Landscape

Assay Landscape

324
Total Assays
290
Tested Compounds
3
Assay Types
Binding — 320 assays, 290 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 263 221 7.1
assay format 34 4 6.0
cell-based format 22 38 6.2
subcellular format 1 27 6.2
ADME — 2 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0
single protein format 1 2 7.6
Functional — 2 assays, 85 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 50 6.6
cell-based format 1 35 7.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine